ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Geir Tangen
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Øvrum, E.
Right arrow Articles by Ringdal, M.-A. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Øvrum, E.
Right arrow Articles by Ringdal, M.-A. L.

Ann Thorac Surg 1996;62:1128-1133
© 1996 The Society of Thoracic Surgeons


Original Articles: Cardiovascular

Heparinized Cardiopulmonary Bypass and Full Heparin Dose Marginally Improve Clinical Performance

Eivind Øvrum, MD, PhD, Einfrid Åm Holen, MD, Geir Tangen, MD, Mari-Anne L. Ringdal, CCP

Departments of Cardiac Surgery and Anesthesiology, Oslo Heart Center, Oslo, Norway

Accepted for publication May 6, 1996.

Background. The use of completely heparin coated cardiopulmonary bypass circuits in combination with a reduced systemic heparin dose has previously been shown to reduce postoperative bleeding after cardiac operations. However, it has remained unknown whether this effect was related to the improved biocompatibility of the heparin-treated surfaces per se or to the reduced exposure to circulating heparin. Therefore we investigated patients undergoing heparin-coated extracorporeal circulation and full systemic heparinization.

Methods. Two hundred seventeen patients having first-time myocardial revascularization were prospectively randomized either to a group in which a completely ("tip-to-tip") heparin-coated circuit (Duraflo II) was used for perfusion (n = 107) or to a control group (n = 110) in which an uncoated, but otherwise identical, circuit was used. Full systemic heparinization was induced in both groups (activated clotting time, >480 seconds). The postoperative blood loss, requirements for homologous blood transfusions, clinical performance, and complications were recorded.

Results. The amount of postoperative mediastinal drainage was nearly identical in the two groups. The mean 18-hour drainage was 694 ± 313 mL in the heparin-coated group and 679 ± 269 mL in the control group (p = not significant). Three patients in the heparin-coated group and 6 patients in the control group received homologous red blood cell transfusions (p = not significant). The incidence of postoperative atrial fibrillation was significantly lower in the heparin-coated group (21.8%) than in the control group (43.1%) (p = 0.002). Otherwise, there were no significant differences in the extubation times, the incidence of perioperative myocardial infarction, the creatinine concentration, the incidence of neurologic dysfunction, the progress in physical rehabilitation, or the hemoglobin concentration at discharge.

Conclusions. The use of completely heparin coated cardiopulmonary bypass circuits and full systemic heparinization in patients undergoing coronary artery bypass procedures did not reduce postoperative bleeding or change clinical performance, except for a significant decrease in the incidence of postoperative atrial fibrillation.




This article has been cited by other articles:


Home page
Eur. J. Cardiothorac. Surg.Home page
O. Mangoush, S. Purkayastha, S. Haj-Yahia, J. Kinross, M. Hayward, F. Bartolozzi, A. Darzi, and T. Athanasiou
Heparin-bonded circuits versus nonheparin-bonded circuits: an evaluation of their effect on clinical outcomes
Eur. J. Cardiothorac. Surg., June 1, 2007; 31(6): 1058 - 1069.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
M. E. Jessen
Pro: Heparin-Coated Circuits Should be Used for Cardiopulmonary Bypass
Anesth. Analg., December 1, 2006; 103(6): 1365 - 1369.
[Full Text] [PDF]


Home page
ChestHome page
L. L. Creswell, J. C. Alexander Jr., T. B. Ferguson Jr., A. Lisbon, and L. A. Fleisher
Intraoperative Interventions: American College of Chest Physicians Guidelines for the Prevention and Management of Postoperative Atrial Fibrillation After Cardiac Surgery
Chest, August 1, 2005; 128(2_suppl): 28S - 35S.
[Abstract] [Full Text] [PDF]


Home page
PerfusionHome page
F D Rubens and T Mesana
The inflammatory response to cardiopulmonary bypass: a therapeutic overview
Perfusion, January 1, 2004; 19(1_suppl): S5 - S12.
[Abstract] [PDF]


Home page
Ann. Thorac. Surg.Home page
G. M. Palatianos, C. N. Foroulis, M. I. Vassili, G. Astras, K. Triantafillou, E. Papadakis, A. A. Lidoriki, E. Iliopoulou, and E. N. Melissari
A prospective, double-blind study on the efficacy of the bioline surface-heparinized extracorporeal perfusion circuit
Ann. Thorac. Surg., July 1, 2003; 76(1): 129 - 135.
[Abstract] [Full Text] [PDF]


Home page
SEMIN CARDIOTHORAC VASC ANESTHHome page
F. D. Rubens and T. Mesana
Surface Modified Cardiopulmonary Bypass Circuits: Modifying the Inflammatory Response
Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2002; 6(4): 301 - 306.
[Abstract] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
M. Johnell, G. Elgue, R. Larsson, A. Larsson, S. Thelin, and A. Siegbahn
Coagulation, fibrinolysis, and cell activation in patients and shed mediastinal blood during coronary artery bypass grafting with a new heparin-coated surface
J. Thorac. Cardiovasc. Surg., August 1, 2002; 124(2): 321 - 332.
[Abstract] [Full Text] [PDF]


Home page
SEMIN CARDIOTHORAC VASC ANESTHHome page
H. A. Hennein
Inflammation After Cardiopulmonary Bypass: Therapy for the Postpump Syndrome
Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2001; 5(3): 236 - 255.
[Abstract] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
E. Ovrum, G. Tangen, R. Oystese, M. A. L. Ringdal, and R. Istad
Comparison of two heparin-coated extracorporeal circuits with reduced systemic anticoagulation in routine coronary artery bypass operations
J. Thorac. Cardiovasc. Surg., February 1, 2001; 121(2): 0324 - 330.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
H. Kumano, S. Suehiro, K. Hattori, T. Shibata, Y. Sasaki, M. Hosono, and H. Kinoshita
Coagulofibrinolysis during heparin-coated cardiopulmonary bypass with reduced heparinization
Ann. Thorac. Surg., October 1, 1999; 68(4): 1252 - 1256.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
P. M. McCarthy, J.-P. P. Yared, R. C. Foster, D. A. Ogella, J. A. Borsh, and D. M. Cosgrove III
A prospective randomized trial of Duraflo II heparin-coated circuits in cardiac reoperations
Ann. Thorac. Surg., May 1, 1999; 67(5): 1268 - 1273.
[Abstract] [Full Text] [PDF]


Home page
PerfusionHome page
J. A. Hyde, J. A Chinn, and T. R Graham
Platelets and cardiopulmonary bypass
Perfusion, December 1, 1998; 13(6): 389 - 407.
[PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1996 by The Society of Thoracic Surgeons.